Expertise in
96
conditions

F S. Fang

No. 2 Zheshan West Road, 
Wuhu, CN 
Expertise in
96
conditions
No. 2 Zheshan West Road, 
Wuhu, CN 
OverviewLocationsClinical Research

Overview

F Fang practices in Wuhu, China. Fang is highly rated in 96 conditions, according to our data. Their top areas of expertise are Pericarditis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Bone Marrow Aspiration, and Vitrectomy.

Their clinical research consists of co-authoring 2622 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

No. 2 Zheshan West Road, Wuhu, China
Other Locations
2600 Donghai Avenue, Bengbu, 233003, China
Union Hospital, Wuhan, 430022, China
Xiamen Branch, Xiamen, China
168 Changhai Road, Shanghai, 200433, China
13 Hangkong Road, Wuhan, 430030, China
1163 Xinmin Avenue, Changchun, 130021, China
No. 5 Jilin Street, Jilin, 132013, China
999 Zhongxing South Road, Shaoxing, 312000, China
No. 2 Anzhen Road, Beijing, 100029, China
No. 600, Yishan Road, Xuhui, China
1 Zhiyuan Road, Guilin, 541199, China
Key Laboratory Of Integrates Regulation And Resource Development On Shallow Lakes, Nanjing, 210098, China
100 Haining Road, Shanghai, 200080, China
Yishan Road 600, Shanghai, 200233, China
The Yangguang South Street And Baiyang East Road, Fangshan, 102488, China
8 Caobao Road, Xuhui, 200235, China
Lushan Road, Changsha, 410081, China
Chongqing Key Laboratory Of Pediatrics, Chongqing, 400014, China
No. 9 Hangda Road, Hangzhou, 310012, China
No. 282 Anqing Road, Hefei, 230061, China
No. 70, Heping Road, Weihai, 264200, China
220 Handan Road, Shanghai, 200433, China
159 Tongxin Road, Tongxin, 200083, China
Key Laboratory of Carcinogenesis and Translational Research
Beijing, China
Central South University 87 Xiang Ya Road, Changsha, 410008, China
Haidian Road, Haidian, 100871, China
1163 Ximin Street, Changchun, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
Enrollment Status: Terminated
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
Enrollment Status: Completed
Publish Date: January 01, 2025
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
View 2 Less Clinical Trials

2622 Total Publications

Modulation of the inflammatory microenvironment after SCI to achieve enhanced nerve regeneration using pteryxin-releasing methylacrylated hyaluronic acid.
Modulation of the inflammatory microenvironment after SCI to achieve enhanced nerve regeneration using pteryxin-releasing methylacrylated hyaluronic acid.
Journal: Biomaterials science
Published: December 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Fang's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 81 Advanced Conditions
View All 379 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile